Goldman Sachs Resumes Celgene (CELG) at Neutral
Tweet
Share
E-mailGet Alerts CELG Hot Sheet
Price: $108.24 --0%
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs resumes coverage on Celgene (NASDAQ: CELG) with a Neutral. PT $77.00.
The firm comments, "We expect the stock's performance in 2013 to be driven by the Street’s view of the likelihood of an EU label expansion for the key cancer drug, Revlimid, but see risk/reward as balanced."
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $81.19 yesterday.
The firm comments, "We expect the stock's performance in 2013 to be driven by the Street’s view of the likelihood of an EU label expansion for the key cancer drug, Revlimid, but see risk/reward as balanced."
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $81.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
- BMO Capital Starts Energy Fuels (UUUU) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
